New combo therapy offers hope for head and neck cancer patients who can't have chemo
NCT ID NCT07333274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps control advanced head and neck cancer better than radiation alone. It is for 335 adults whose cancer has spread locally but who cannot take platinum-based chemotherapy. The main goal is to see if the combination keeps the cancer from growing or coming back for longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGShandong, Province, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an immunotherapy combo shrink throat tumors before surgery?
- Could a Pre-Chemo drug shield bone marrow in head and neck cancer?
- New study: can early palliative care help head and neck cancer patients suffer less?
- New lozenge aims to ease radiation mouth sores for hours
- Proton therapy offers new hope for head and neck cancer patients facing second radiation